No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 4, 2012, Pages 429-432

  Byrne, Robert A ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

biodegradable polymer; biolimus A9; drug eluting stent; sirolimus; stent thrombosis

Indexed keywords

EVEROLIMUS; POLYMER; RAPAMYCIN; UMIROLIMUS;

ACUTE CORONARY SYNDROME; BARE METAL STENT; BIODEGRADABILITY; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; DRUG SAFETY; HUMAN; LONG TERM CARE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84859466393     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.29     Document Type: Review

References (14)

1. Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27(7), 1500-1510 (2007). (Pubitemid 46986103)
2. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 369(9562), 667-678 (2007). (Pubitemid 46281313)
3. Byrne RA, Iijima R, Mehilli J et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc. Interv. 2(4), 291-299 (2009).
4. Raber L, Wohlwend L, Wigger M et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: Results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation 123(24), 2819-2828 (2011).
5. Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46(2), 231-236 (2005). (Pubitemid 40966848)
6. Hamilos MI, Ostojic M, Beleslin B et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol. 51(22), 2123-2129 (2008). (Pubitemid 351721001)
7. Nakazawa G, Otsuka F, Nakano M et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J. Am. Coll. Cardiol. 57(11), 1314-1322 (2011).
8. Byrne RA, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol. 57(5), 567-584 (2009).
9. Garg S, Serruys PW. Coronary stents: Looking forward. J. Am. Coll. Cardiol. 56(10 Suppl.), S43-S78 (2010).
10. Joner M, Byrne RA. The importance of preclinical research in contemporary interventional cardiology. EuroIntervention 6(1), 19-23 (2010).
11. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 372(9644), 1163-1173 (2008).
12. Stefanini GG, Kalesan B, Serruys PW et al. Long-Term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378(9807), 1940-1948 (2011).
13. Byrne RA, Kastrati A, Kufner S et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur. Heart J. 30(20), 2441-2449 (2009).
14. Byrne RA, Kastrati A, Massberg S et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J. Am. Coll. Cardiol. 58(13), 1325-1331 (2011).